Congress Passes Bills Making Major Investments in Alzheimer’s
23 mars 2024 10h15 HE
|
UsAgainstAlzheimer's
Congress passes major investments in the fight against Alzheimer’s.
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages InMode Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INMD
22 mars 2024 18h39 HE
|
The Rosen Law Firm PA
NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of InMode Ltd. (NASDAQ: INMD) between June 4, 2021 and...
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
22 mars 2024 17h04 HE
|
NurExone Biologic Inc
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
FDA Clears RedDrop Dx, Inc.’s Blood Collection Device, RedDrop One
22 mars 2024 10h59 HE
|
Innosphere Ventures
Fort Collins, CO, March 22, 2024 (GLOBE NEWSWIRE) -- RedDrop Dx, Inc., Innosphere Ventures Client Company, is pleased to announce that its innovative blood collection device, RedDrop One, has...
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
19 mars 2024 08h00 HE
|
Cocrystal Pharma, Inc.
Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash., March 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or...
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
19 mars 2024 07h00 HE
|
Revive Therapeutics Ltd.
TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Dream Valley x Outlast Technologies Launch Cooling Comforter with NASA-grade Aerospace Temperature Regulating Technology
15 mars 2024 09h05 HE
|
Dream Valley
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Dream Valley®, a leading innovator in sleep technology, has introduced its Dream Valley Cooling Comforter featuring the Outlast® temperature-regulating...
FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
14 mars 2024 17h18 HE
|
Global Liver Institute
Washington, DC, March 14, 2024 (GLOBE NEWSWIRE) -- Today, Global Liver Institute (GLI) recognizes the importance of the first approval by the U.S. Food and Drug Administration (FDA) of a medication...
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
14 mars 2024 15h11 HE
|
Spherix Global Insights
EXTON, PA, March 14, 2024 (GLOBE NEWSWIRE) -- The past several years have brought a transformative shift to the IgA nephropathy (IgAN) treatment landscape, including the introduction of two new...
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
14 mars 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma advises of expected FDA response a month later than anticipated. Prepares for June 1, 2024, start of trial of tafenoquine for babesiosis.